WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN) announced today that it intends to offer
for sale its common stock in an underwritten public offering. The
offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
Morgan Stanley & Co. LLC and Jefferies & Company, Inc. are acting as
joint book-running managers for the proposed offering.
The securities described above are being offered by ImmunoGen pursuant
to an automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC). This
press release does not constitute an offer to sell or a solicitation of
an offer to buy the securities in this offering, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction. A preliminary prospectus supplement related
to the offering will be filed with the SEC and will be available on the
SEC's website located at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained, when available,
from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, NY 10014, by telephone at 866-718-1649, or
by email at email@example.com
and from Jefferies & Company, Inc., Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by
telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to
deliver one of ImmunoGen's proprietary cancer-cell killing agents
specifically to tumor cells. There are now ten TAP compounds in clinical
development, of which three are wholly owned by ImmunoGen. ImmunoGen's
collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly,
Novartis, Roche and Sanofi. The most advanced compound using ImmunoGen's
TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech, a member of the
This press release includes forward-looking statements, including
statements related to the proposed public offering of securities by
ImmunoGen. For these statements, ImmunoGen claims the protection of the
safe harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that there
are risks and uncertainties related to the public offering. A review of
these risks can be found in ImmunoGen's Annual Report on Form 10-K for
the fiscal year ended June 30, 2011 and other reports filed with the
Securities and Exchange Commission. ImmunoGen undertakes no
obligation to revise or update any forward-looking statement to reflect
events or circumstances after the issuance of this press release.
Carol Hausner, 781-895-0600
Director, Investor Relations
and Corporate Communications
Source: ImmunoGen, Inc.
News Provided by Acquire Media